Stocks
GlaxoSmithKline (GSK) EBITDA US GAAP (year values) |
|||||||||
| 2021 | 2022 | 2022 | 2023 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA, £ | ? | 8 786 000 000 | 8 805 000 000 | 8 805 000 000 | 9 412 000 000 | 9 287 000 000 | 9 544 000 000 | ||
| Changes by years, y/y, % | 0% | +0% | 0% | +7% | -1% | +4.8% | |||
GlaxoSmithKline. EBITDA US GAAP, £
GlaxoSmithKline. EBITDA US GAAP, changes, %
GlaxoSmithKline. EBITDA US GAAP, sum by quarters, £
GlaxoSmithKline (GSK) EBITDA US GAAP (quarter values) |
||||||||
| 2023Q2 | 2023Q3 | 2023Q4 | 2023Q4 | 2024Q1 | LTM ? | |||
| EBITDA, £ | ? | 2 624 000 000 | 2 552 000 000 | 2 230 000 000 | 2 230 000 000 | 2 532 000 000 | 9 544 000 000 | |
| Changes by years, y/y, % | +52% | +18% | +18% | +18% | -8% | |||
| Changes by quarters, q/q, % | 0% | -3% | -13% | 0% | +14% | |||
